Infleqtion director granted 64,690 stock options
Infleqtion, Inc. director David B. Singer reported receiving two grants of stock options totaling 64,690 options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Infleqtion, Inc. director David B. Singer reported receiving two grants of stock options totaling 64,690 options. One block of 34,740 fully vested options reflects legacy ColdQuanta, Inc. awards that were automatically converted into Infleqtion options in connection with the Churchill Capital Corp X–ColdQuanta mergers and subsequent name change to Infleqtion, Inc.
The second grant covers 29,950 options tied to his board service, with one-third vesting on February 17, 2027 and the remainder vesting monthly over three years, subject to continued service. The economic benefit of his director compensation flows to Maverick Ventures Investment Fund, L.P. through a management fee offset, and Singer disclaims beneficial ownership except to the extent of his pecuniary interest.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 34,740 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) | 29,950 | $0.00 | $0.00 |
Footnotes (5)
- F1. Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of September 8, 2025, by and among Churchill Capital Corp X, a Delaware corporation now known as Infleqtion, Inc. ("Acquiror"), AH Merger Sub I, Inc., a direct, wholly-owned Subsidiary of Acquiror ("Merger Sub I"), AH Merger Sub II, LLC, a direct, wholly-owned Subsidiary of Acquiror ("Merger Sub II" and together with Merger Sub I, "Merger Subs") and ColdQuanta, Inc. (the "Company") pursuant to which (a) Merger Sub I was merged with and into the Company, and the Company continued as the surviving corporation and immediately thereafter, (b) the Company merged with and into Merger Sub II, and Merger Sub II became the surviving company and continued in existence as a wholly-owned subsidiary of Acquiror (collectively, the "Mergers"). In connection with the Mergers, Acquiror changed its name to Infleqtion, Inc. (the "Issuer").
- F2. Fully vested.
- F3. Pursuant to the Mergers, the legacy stock options of the Company were automatically converted into the right to receive stock options of the Issuer with the same terms and conditions.
- F4. The economic benefit of the director compensation provided in respect of the Reporting Person's board service passes to Maverick Ventures Investment Fund, L.P. through a management fee offset. The Reporting Person disclaims, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
- F5. 1/3rd of the shares underlying the option shall vest on February 17, 2027, and 1/36th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did David B. Singer report for CCCX?
How many Infleqtion (CCCX) stock options were granted to David B. Singer?
What is the vesting schedule of David B. Singer’s new CCCX option grant?
How did the Churchill Capital Corp X and ColdQuanta merger affect CCCX stock options?
Who receives the economic benefit of David B. Singer’s director compensation at CCCX?
Are David B. Singer’s converted CCCX options immediately exercisable?
AI-generated analysis. How Rhea-AI works. Not financial advice.